重大事件
即時報告
8-K
2026-06-02
Taysha Gene Therapies 提交 8-K 披露股東投票結果
AI 繁中摘要
Taysha Gene Therapies, Inc. 於 2026 年 6 月 2 日向 SEC 提交一份 8-K 申報，報告日期為 2026 年 6 月 1 日。該申報屬項目 5.07「提交事項予證券持有人投票」，即披露公司召開股東大會並就若干事項進行投票表決的結果。雖然申報文件中未列出具體投票細項或通過議案，但投資者可於完整 8-K 內查閱參與人數、贊成/反對票數等關鍵數據。此類申報本身不直接反映經營業績，惟股東投票結果（如董事選舉、薪酬方案或重大交易批准）可能影響公司治理方向及未來決策。作為一家專注生物製品（基因治療）的企業，Taysha 的股東表決動向對了解其內部共識及戰略穩定性具一定參考價值。
展開英文正文
EDGAR Filing Documents for 0001193125-26-253478 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-253478 Filing Date 2026-06-02 Accepted 2026-06-02 16:05:28 Documents 11 Period of Report 2026-06-01 Items Item 5.07: Submission of Matters to a Vote of Security Holders Interactive Data Document Format Files Seq Description Document Type Size 1 8-K d159199d8k.htm iXBRL 8-K 37517 Complete submission text file 0001193125-26-253478.txt 152724 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA tsha-20260601.xsd EX-101.SCH 3170 3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20260601_lab.xml EX-101.LAB 17991 4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20260601_pre.xml EX-101.PRE 11254 14 EXTRACTED XBRL INSTANCE DOCUMENT d159199d8k_htm.xml XML 3637 Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000 Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings) EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 261055898 SIC: 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)